Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has released the video presentations conducted at the end of its Annual General and Special Meeting held on October 2, 2015 in Toronto, Canada.

The presentations were delivered by Roger Dumoulin-White, President and CEO of Theralase, Dr. Lothar Lilge, Senior Scientist, Princess Margaret Cancer Center, University Health Network (“UHN”) and Dr. Girish Kulkarni, Uro-Oncologist, also from UHN.

The videos of the presentation may be viewed at:

AGM 2014 - Roger Dumoulin-White

https://www.youtube.com/watch?v=3Zz7CkBRDN8&feature=youtu.be

Dr Kulkarni & Dr Lilge - Theralase AGM 2014

https://www.youtube.com/watch?v=78rigjdgZSk&feature=youtu.be

Roger Dumoulin-White, President and CEO, Theralase stated that, “Theralase has made significant strides forward in 2015 in both the commercialization of its next generation TLC-2000 therapeutic laser system and its TLC-3000 anti-cancer technology focused on the destruction of Non-Muscle Invasive Bladder Cancer. The TLC-2000 is on track to launch in Canada in 4Q2015, while the TLC-3000 is also on track to commence enrolling patients in late 4Q2015. 4Q2015 will prove to be a significant quarter for the completion of milestones in the history of Theralase.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com .

Theralase Technologies Inc. was recognized as a TSX Venture 50® company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Michael Borovec

Director of Investor Relations

1.866.THE.LASE (843-5273) ext. 222

416.699.LASE (5273) ext. 222

mborovec@theralase.com

www.theralase.com

To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/theralase10082015.pdf

Source: Theralase Technologies Inc. (TSX Venture:TLT, OTC Pink:TLTFF) http://theralase.com/

Maximum News Dissemination by FSCwire. http://www.fscwire.com

Copyright © 2015 Filing Services Canada Inc.